This funding opportunity supports rigorous validation of transformative, multi-use platforms or technologies aimed at accelerating early detection, screening, diagnosis, treatment, control, behavior, prevention, or epidemiology of HLBS-related diseases. It excludes clinical trials and emphasizes development of translational researchers skilled in product development and entrepreneurship. Eligible applicants include diverse U.S.-based institutions and organizations, with foreign components of U.S. entities allowed.
Eligible applicants include a wide range of U.S.-based institutions such as private and public higher education institutions, nonprofits, for-profit organizations, small businesses, tribal governments, and various government entities. Non-domestic entities are not eligible, but foreign components of
